diff --git a/inbox/archive/health/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md b/inbox/archive/health/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md
index 3e956983..baefdce1 100644
--- a/inbox/archive/health/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md
+++ b/inbox/archive/health/2026-03-22-health-canada-rejects-dr-reddys-semaglutide.md
@@ -8,8 +8,13 @@ domain: health
 secondary_domains: []
 format: news article
 status: processed
+status: enrichment
 priority: high
 tags: [semaglutide-generics, glp1, dr-reddys, health-canada, canada, regulatory, patent-cliff, obeda]
+processed_by: vida
+processed_date: 2026-03-22
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -51,3 +56,13 @@ tags: [semaglutide-generics, glp1, dr-reddys, health-canada, canada, regulatory,
 PRIMARY CONNECTION: GLP-1 receptor agonists claim ("inflationary through 2035") and the Session 21 claim candidate about Dr. Reddy's 87-country rollout
 WHY ARCHIVED: Corrects the Session 9 projection; establishes regulatory friction as an underappreciated barrier to generic GLP-1 global rollout
 EXTRACTION HINT: The claim candidate from Session 9 about Dr. Reddy's clearing 87 countries for 2026 rollout needs updating — Canada is NOT in the 2026 timeline. The extractor should flag this as a correction to Session 9's claim candidate 2.
+
+
+## Key Facts
+- Dr. Reddy's received a non-compliance notice (NoN) from Canada's Pharmaceutical Drugs Directorate in October 2025
+- Canada's semaglutide patents expired January 2026
+- Dr. Reddy's projected May 2026 Canada launch in its 87-country rollout plan
+- Regulatory re-submission and review timeline: 8-12 months minimum
+- Dr. Reddy's stated it is 'in constant touch with Canadian regulators' and has 'sent replies to their queries'
+- The Canada launch is 'on pause' per company statement
+- India launch of Obeda (generic semaglutide) confirmed March 21, 2026